Therapeutic area intelligence for Dopamine Agonist with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 1

Companies

Esjay Pharma →

Assets

PARLODEL →

Renata →

Recent signals(2)

RegulatoryJuly 9, 2026

FDA Accepts Supplement for PARLODEL by Esjay Pharma

The FDA has accepted a supplemental application for PARLODEL (bromocriptine mesylate) from Esjay Pharma.

StrategyJune 23, 2026

FDA Grants Approval for Cabergoline ANDA220309 by Renata

The FDA has granted approval for ANDA220309, a generic version of cabergoline submitted by Renata.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.